The number of amino acid residues in hydrophilic loops connecting transmembrane domains of the GABA transporter GAT-1 is critical for its function  by Kanner, Baruch I. et al.
FEBS Letters 356 (1994) 191-194 
FEBS 14868 
The number of amino acid residues in hydrophilic loops 
transmembrane domains of the GABA transporter GAT-1 
its function 
connecting 
is critical for 
Baruch I. Kanner*, Annie Bendahan, Shifrah Pantanowitz, Hailing Su 
Department of Biochemistry, Haakah Medical School, The Hebrew University, PO Box 12272, Jerusalem 91120, Israel 
Received 20 October 1994; revised version received 4 November 1994 
Abstract Transporter proteins consist of multiple transmembrane domains connected by hydrophillic loops. As the importance of these loops in 
transport processes is poorly understood, we have studied this question using the cDNA coding for GAT-1, a Na+/Cl--coupled y-aminobutyric acid 
transporter f om rat brain. Deletions of randomly picked non-conserved single amino acids in the loops connecting helices 7and 8 or 8 and 9 result 
in inactive transport upon expression i  HeLa cells. However, transporters where these amino acids are replaced with glycine retain significant activity. 
The expression levels of the inactive mutant ransporters was similar to that of the wild-type, but one of these, dval-348, appears to be. defectively 
targetted to the plasma membrane. Our data are compatible with the idea that a minimal ength of the loops is required, presumably to enable the 
transmembrane domains to interact optimally with each other. 
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1. Iutroduction 
High affinity sodium-dependent transporters are thought to 
play an important role in the overall process of synaptic trans- 
mission [ 1,2]. They catalyze sodium-coupled transport of neu- 
rotransmitters into presynaptic nerve terminals and fine proc- 
esses of glial cells which are in close contact with the synapse 
[3,4]. The y-aminobutyric acid (GABA) transporter GAT-1 
was purified to near homogeneity using a rapid reconstitution 
assay [5,6] and is an 80-kDa glycoprotein which represents 0.1% 
of the membrane protein. It is predominantly located in nerve 
terminals [3] and catalyzes the electrogenic co-transport of 
GABA with one chloride and two sodium ions [7-g]. GAT-1 
was the first neurotransmitter transporter to he cloned and 
expressed [lo]. The deduced protein has 599 amino acids with 
a calculated molecular weight of 67,084 Da [lo]. This is in good 
agreement with the molecular weight of the deglycosylated 
GABA transporter [l 11. Hydrophathy plot analysis predicts 
twelve putative membrane-spanning a-helices [lo]. After the 
subsequent expression cloning of NET-I, a norepinephrine 
transporter [12], it became clear that they are members of a 
novel family. Indeed, many other neurotransmitter trans- 
porters, including at least three other GABA isotransporters, 
were then cloned and shown to he related to GAT- 1 and NET-l 
(for reviews see [13-161). 
We have shown that the amino- and carboxyl-terminal tails 
of GAT-1 are not required for its function [17,18] but the 
membrane domains are [ 181. Indeed, we have identified several 
amino acid residues within the putative transmembrane do- 
mains which are critical for the function of GAT-I [19,20]. The 
role of the hydrophilic loops connecting the putative transmem- 
brane domains is thus far unexplored, not only in GAT-1 hut 
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also in other transport proteins. In this paper we provide evi- 
dence compatible with the idea that at least one of their roles 
is to permit the appropriate interaction of those transmem- 
brane helices which are adjacent to each other in the structure 
of the transporter. 
2. Materials and methods 
2.1. Site-directed mutagenesis 
Mutagenesis was performed as described in [21]. The shortened 
GAT-1 clone [19] was used to transform Escherichia coli CJ 236 to 
ampicillin resistance. From one of the transfommnts ingle-stranded 
uracil-containing DNA was isolated upon growth in a uridinecontain- 
ing medium according to the standard protocol from Stratagene, using 
helper phage b. This yields the sense strand, and consequently the 
mutagenic primers were designed to be antisense. 
The primers used to make the mutations are presented in Table 1 
(names in parenthesis). 
Mutations/deletions were confirmed by DNA sequencing and sub- 
cloned into the wild-type strain using the restriction enzymes PpuMI 
and Age1 for 4348-369; BsmI and Age1 for 4404408, AL408 and 
L408G and PpuMI and Bsml for all the others. 
The subcloned DNAs were sequenced from both directions between 
the sites of the indicated restriction enzymes. 
2.2. Cell growth and expression 
HeLa cells were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal calf serum, 200 units/ml penicillin, 
200 &ml streptomycin, and 2 mM glutamine. Infection with recombi- 
nant vaccinia/T7 virus vTF7-3 and subsequent transfection with plas- 
mid DNA was done as described 1221. GABA transport and im- 
munoprecipitation were done as published previously [19]. Protein was 
determined as described [23]. SDS-PAGE was as described [24] using 
a 4% stacking and 10% separating el. Size standards (Pharmacia LKB 
Biotechnology Inc.) were run in parallel and visualized by Coomassie 
blue staining. Reconstitution of transporters in proteoliposomes was 
used to differentiate between those exposed at the membrane surface 
and those located within the cell. Reconstitution of transport was done 
as follows. For each experiment infected/transfected cells from two 
large wells (35 mm diameter) were used for each mutant. They were 
washed twice with 1 ml of phosphate-buffered saline and taken up in 
a small volume of phosphate buffered saline using a rubber policeman. 
To 35 ~1 of this suspension were added (in this order) 15 ~1 of 0.1 M 
KP, (pH 7.5) and 10 ~1 of 20% cholic acid (neutralized by NaOH). After 
All rights reserved. 
192 
Table 1 
B.I. Kanner et al. IFEBS Letters 356 (1994) 191-194 
5'-TAG CTG TGT CAC AGC CTC ATG AGC CAT OAA GCC CAC-3’ (A348-369) 
5’-GTA TGC CAA GAA TGC CAG GGA CCT CTT GGT GAC ATG-3' (A353-362) 
5'-CAC ATC GGC TAT GGA ATG AGC CAT GAA GCC-3’ (A348-351) 
5’-ATC GGC TAT GGA CCT ATG AGC CAT GAA GCC-3’ (A348-350) 
5’-GGC TAT GGA CCT CTT ATG AGC CAT GAA GCC-3’ (A348-349) 
5’-TAT GGA CCT CTT GGT ATG AGC CAT GAA GCC-3’ (AV348) 
5’-CAC ATC GGC TAT GGA CTT GGT GAC ATG AGC-3' (AR3511 
5’-CAG TCC AGG GCC TGA CGC CAC ATC GGC TAT-3’ (AA3581 
5'-ACC TCT TOG TGC CAT GAG CCA TGA A-3' (V348G) 
5'-ACC TCT TOG TGA TAT GAG CCA TGA A-3' (V3481) 
5'-ATC GGC TAT GGA CCC CTT GGT GAC ATG A-3' (R351G) 
5'-AGT CCA GGG CCT GAG CCC GCC ACA TCG GCT AT-3’ (A358G) 
5’-TGG ACC TCT TGG TGT TAA CAT GAG CCA TGA-3’ (Ins-N349) 
5’-GGT ACT CAT CCA CGC CCT CCA COG TAC AGA A-3' (A404-408) 
5'-GGG GTA CTC ATC CAC GGC AGT GAT GAA GCC-3’ (AL408) 
5’-GTA CTC ATC CAC CCC GGC AGT GAT GAA-3’ (L408G) 
10 min incubation on ice, the mixture was reconstituted with asolectin! 
brain lipids using spin columns, and transport was measured exactly as 
described [5]. 
2.3. Materials 
Polynucleotide kinase, DNA polymerase and DNA ligase (all from 
T4) were from Boehringer-Mannheim. Restriction enzymes were from 
New England Biolabs and Boehringer-Mannheim. Sequenase kits (ver- 
sion 2.0) were from US Biochemicals. D-[%]aATP (1,000 Ci/mmol) 
and [35S]methionine (1,000 Wmmol) were from Amersham. [‘H]GABA 
(47.6 Wmmol) was from the Nuclear Research Center, Negev, Israel. 
The tissue culture medium, serum, penicillin/streptomycin and L-glu- 
tamine were from Biological Industries, Kibbutz Bet Ha’Emek, Israel. 
Transfection reagent (DOTAP) was from Boehringer. The vaccinia/T7 
recombinant virus was a gift from Dr. Bernard Moss (NIH). Brain 
lipids were prepared from bovine brain as published [25]. Protein 
A-Sepharose CL-4B, asolectin (P-5638, type II S) valinomycin, uridine, 
cholic acid and all other materials were obtained from Sigma. The 
antiserum against residues 571-586 of the GAT-1 transporter, 
IQPSEDIVRPENGPEQ (PcooH, part of the carboxy-terminal) was a 
generous gift from Dr. Reinhard Jahn (Yale University Medical School, 
New Haven, CT) and has been documented before [18-201. 
3. Results and discussion 
A series of ever smaller deletions in the hydrophilic loop 
connecting putative transmembrane a-helices 7 and 8 of GAT-1 
(loop 7-8) has been produced. None of these deleted trans- 
porters, which include 4348-369 (a deletion from amino acid 
348-369), 4353-362, 4348-351, 4348-350 and 4348-349, ex- 
hibit significant transport activity when expressed in HeLa cells 
using the vaccinialT7 recombinant virus [26]. In all cases it is 
less than 2% of the transport activity observed with the wild- 
type. This phenomenon is probably not confined to loop 7-8, 
as a small deletion in loop 8-9,4404-408, also causes defective 
transport. In order to maximize the chance to observe transport 
activity, we have examined the effect of deleting individual 
amino acids which are not conserved within the transporter 
superfamily. Four such transporters have been constructed 
with deletions in Val-348 (AV348), Arg-351 (AR351) and Ala- 
358 (AA358) - all located in loop 7-8 -as well as one in Leu-408 
(AlAO8) in loop 8-9. None of these deleted transporters exhibit 
significant transport activity (Fig. 1). On the other hand trans- 
porter mutants where these amino acids are replaced by others, 
exhibit considerable activity. When Val-348 is mutated to the 
conserved isoleucine (V3481), activity is at least as high as in 
the wild-type (Fig. 2). When it is replaced by glycine, consider- 
able activity is detected in the V348G transporter (Fig. 2). This 
indicates that even though at this position a hydrophobic amino 
acid is optimal, the Val residue is clearly not essential for activ- 
ity. This is in contrast to the essential amino acids Arg-69 ([19] 
or Trp-222 [20] where replacement even by closely related 
amino acids rendered the transporter completely non-func- 
tional. Also in the case of Arg-351 and Leu-408 a similar situ- 
ation occurs to that of Val-348. In all three positions replace- 
ment by a glycine results in transporters exhibiting 3@45% of 
wild-type activity. On the other hand, replacement of Ala-358 
by glycine results in a fully active transporter. This is presuma- 
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Fig. 1. [3H]GABA transport by GAT-1 transporters containing single 
amino acid deletions in loops 7-8 and 8-9. Sodium-dependent transport 
was measured in HeLa cells transiently expressing wild-type (pT7- 
GAT-1) or mutated transporters, as described in section 2. The results 
are expressed as a percent of the corresponding values of the wild-type. 
Each bar represents mean f S.E.M. of five different experiments, each 
done in triplicate. 
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Fig. 2. [‘HIGABA transport by GAT-I transporters containing replaee- 
ments or insertions in loops 7-8 and 8-9. This was performed exactly 
as described in the legend to Fig. 1. Each bar represents mean f S.E.M. 
of four different experiments, each done in triplicate. 
bly because of the similarity of these two amino acids. The 
above results suggest that, at least at 4 randomly selected non- 
conserved positions, it is not the deleted amino acid which is 
critical for transport activity. Rather, it appears that the num- 
ber of amino acids in the loop is the important parameter. A 
possible explanation may be that a minimal length of the loops 
is required to allow the transmembrane-spanning helices they 
are connecting, to occupy their correct position within the 
structure of the transporter. If this is correct, small insertions 
may be expected not to impair the activity of the transporter. 
As shown in Fig. 2, when an asparagine is inserted between 
Val-348 and Thr-349 (Ins-N349) considerable transport activity 
is observed. 
The lack of activity of transporters in which a single amino 
acid was deleted at various positions in the loops is not due to 
decreased steady-state l vels. Cells, expressing mutant or wild- 
type transporters, have been labelled with [3sS]methionine, 
lysed and subsequently the transporters have been immunopre- 
cipitated using an antibody directed against the carboxyl-termi- 
nal of GAT- 1 [ 18-201. As published previously, the transporter 
runs as a band of around 67 kDa [18-201. Even though the 
levels of some of the mutant transporters are somewhat lower 
than those of the wild-type, significant amounts are present in 
all of them (Fig. 3). This indicates that it is not the synthesis 
and turnover of the mutant transporters which are the cause 
for their defective activity. 
The possibility that impaired activity is due to defective tar- 
geting of the mutant transporters to the plasma membrane was 
investigated using a solubilizationlreconstitution assay [20]. 
One would expect that cells expressing a mutant transporter 
that is intrinsically active, but is inefficiently targeted to the 
plasma membrane, would have a cryptic transport activity. 
Detergent extraction of the cells expressing such transporters 
followed by reconstitution of the solubilized proteins, is likely 
to yield transport activity in the proteoliposomes even if they 
were originally residing in internal membranes. Although the 
activity of three of the reconstituted mutant transporters is still 
193 
low compared to the wild-type, in some cases their relative 
activity is increased (Figs. 1 and 4). A marked increase of 
transport activity is observed with mutant dv348. After solubil- 
ization and reconstitution, the transport of this mutant is 
around 30% of that of the wild-type (Fig. 4). This value is 
similar to that of transport of the replacement mutant V348G 
in intact cells (Fig. 2). Thus, it appears that the defective trans- 
port of this deletion mutant by and large is due to defective 
targeting. It is plausible that small deletions in the loop may 
have subtle effects on the structure of the transporter. This may 
influence targeting to the plasma membrane or the functionality 
of the transporter. No information as yet is available as to 
which helices are in direct contact with each other. It is very 
likely that helix 8, for instance, is not interacting with helix 7, 
but with others. A certain minimal length of loop 7-8 is appar- 
ently required to enable helix 8 to do so. The simplest explana- 
tion of our data is that, when this loop is shortened by as little 
as one amino acid residue, this interaction may be strained, 
causing impaired transporter function or targeting. An alterna- 
tive explanation is that perhaps parts of the loops could assume 
an a-helical conformation. Deletion of amino acids may align 
a different set of residues on one side of the helix, from the point 
of the deletion onwards. The fact that insertion of an asparag- 
ine in this part of the loop has relatively little effect on activity 
as compared to deletion of single amino acids (Figs. 1 and 2) 
renders this alternative less likely. 
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Fig. 3. Immunoprecipitation f wild-type and mutant ransporters. 
HeLa cells were infected with the vacciniti7 recombinant virus and 
transfected as indicated below. After labelling with [“S]methionine, 
cells were lysed and the transporters were immunoprecipitated as e- 
scribed in section 2. The DNA used to transfect was pT7-GAT-1 (wild 
type, lane 1); vector alone (pBluescript SK, lane 2); AV348 (lane 3); 
AR351 (lane 4); AA358 (lane 5); and AL408 (lane 6). 
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Fig. 4. rH]GABA transport in proteoliposomes inlaid with wild-type 
or mutant transporters. HeLa cells transiently expressing the indicated 
transporters were solubilized, reconstituted and sodium-dependent 
transport was measured as described in section 2. The results are ex- 
pressed as a percent of the corresponding values of the wild-type. Each 
bar represents mean f S.E.M. of four different experiments. 
It is likely that this phenomenon is not restricted to GAT-1. 
It may be that the concept that a minimal length of the loops 
is required to allow the appropriate transmembrane domains 
to interact appropriately is a general one. It may be applicable 
to other transporters, channel proteins as well as to receptors. 
Finally it should be noted that we have been studying dele- 
tions of amino acids which are poorly conserved. However, 
many of the loops contain highly conserved regions. It is very 
likely that their function is not only to ensure the appropriate 
length of the loops. Those amino acid residues might partici- 
pate in crucial tasks such as substrate binding or in conforma- 
tional changes accompanying the transport process. In fact, in 
the case of a voltage-dependent potassium channel, one of the 
loops appears to contribute to ion selectivity [27]. The partici- 
pation of conserved parts of the loops of GAT-1 and other 
transporters in their function is an important area of future 
research. 
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